

### HEALTHY, FIT & STRONG AUGUST 2006

# 36.6 AT GLANCE

consolidated sales in 2005

million

million

over 300

**~310** current market capitalization 20% of shares were placed at IPO in 2003 at \$9 per share

top-line annual growth: 51% in retail, 33% - in 45% manufacturing

under management in 22 Russian regions (as of July, 2006)

over 34 million

582

pharmacies

purchases in 2005; 0,6 mln. purchases per week; 2,6 mln. purchases per month



skilled personnel and experienced management team


# **OPPORTUNITIES**

We strive to be Russia's leading health & beauty retailer and to become the preferred source of medicines and health & beauty products for Russian consumers


Pursuing industry and internal growth

- Creating a unique customer value proposition
  - Expanding into rapidly growing regions
  - Developing and sustaining a profitable business model
  - Introducing best standards of corporate governance

# 4 HEALTHCARE MARKET GROWTH



## **STORES GROWTH**



NET SALES, USD-millions

NUMBER OF STORES, eop

# **RETAIL TECHNOLOGIES**

We elaborate the retail technology, we introduce innovative products, we create unique customer's shopping experience □ Store formats

Innovative products

Exclusive customer offerings

Private Label

□ Hard traffic in pharmacies

Personnel Training Centre

## **SAFETY & EXCITEMENT**

Unique **36.6** Customer Value Proposition



#### **CONVENIENT LOCATIONS**



WIDE ASSORTMENT



**RELIABLE QUALITY PRODUCTS** 




**COMPETITIVE PRICES** 

## **SHOPPING EXPERIENCE**

Almost all the Muscovites visited **36.6** pharmacies ones and prefer shopping there rather than in any other pharmacy

> A/R/M/I-Marketing data, June, 2005



# LOYALTY PROGRAM

## $MALINA^{TM}$ is a

*joint loyalty program to gather leading companies of the Russian consumer sector* 

*In the first 10 weeks more than 1 mln. cards were issued* 








## **O BRAND AWARENESS**

**36.6** enjoys toplevel brand awareness among most successful retail brands

**93%** prompted and **68%** unprompted brand awareness, highest among Moscow pharmacy chains

*Sources: Gallup Media Survey'05 A/R/M/I-Marketing data, June, 2005* 



100

#### 1 DIFFERENTIATION PRIVATE LABEL

36.6 is the first pharmacy chain to develop private label products, having currently 48 SKU's launched in autumn of 2005. Current turnover is less than 1% of total sales

**150** SKU's are in the pipeline for 2006-2007




#### DIFFERENTIATION **ASSORTMENT**


BOOTS private-label products

**OPTICS** 

VICHY concept-store & skin-care centers








As of July, 2006


# 14 36.6 – THE CONSOLIDATOR OF CHOICE

Regional penetration will be achieved both through organic openings and acquisitions of the regional chains

This is subject to successful competition with a few other chains developing nationwide

Source: Pharmexpert, Q12006





## 5 AGING PHARMACIES PERFORMANCE

Same store sales were up **15.3**% yoy in the 1st half of 2006


#### OLD PHARMACIES

pharmacies opened before 2005

#### NEW PHARMACIES

pharmacies opened in 2005

ALL PHARMACIES



#### As of 9M2005, percentage of generated sales

GROSS MARGIN

PHARMACY PROFIT MARGIN

# 16 KEY PERFORMANCE INDICATORS



\* Please note, that in 2005 the Company regrouped certain business-units

## 7 ORGANIZATION CHART

#### • OAO PHARMACY CHAIN 36.6

ZAO PHARMACIES 36.6 Retail, Moscow

REGIONAL COMPANIES Retail

ACQUIRED GROUPS Retail

BRANCHES Retail OAO VEROPHARM\* Manufacturing

ZAO VREMJA Wholesale

ZAO PHARMSTATE Real estate

KLADA VENTURES Trade Mark

\* currently 49.9% of shares are free-float

## **18 BOARD OF DIRECTORS**

Decision making is ensured by the balanced opinion of both shareholders and that of independent directors

Sergey KRIVOSHEEV Chairman, Co-founder

Artem BEKTEMIROV CEO, Co-founder Michael OBERMAYER Independent director, Director Emeritus of McKinsey & Company

Vassily RUDOMINO, Independent director, Partner in ALRUD law firm Vladimir STOLIN, Independent director, Chairman in ECOPSY consulting firm

## **9 MANAGEMENT STRUCTURE**

Planning and operational controls are performed across the regional business units and product categories

Brand integrity and management as well as strategic business development and expansion are corporate major priorities

CEO		
ANTON PARKANSKY Managing director	SBORETS YULIA CFO	VICTOR VASILIEV Legal Council
<b>DMITRY GODUNOV</b> Operations 1st Deputy MD	OLGA ALTUNINA Human Resources	OLEG ANIKIN Strategy
ALEXANDRA KOZHAEVA Commercial director	<b>BORIS RYABOV</b> Business Technology Development	ANDREI SLIVCHENKO Corporate Finance & Investor Relations
	<b>DMITRY KOZOREZOV</b> Medical director	<b>DARYA KAPLUNOVA</b> Marketing
	DECIONAL	

CATEGORY DIRECTORS

**ARTEM BEKTEMIROV** 

REGIONAL BUSINESS UNITS

#### 20 SHARE PRICE RTS: APTK



Shares placed at MICEX at \$9 per share

About 30% are currently in the free float



M.CAP \$310 MLN

AS AT 1 August'06

Feb- Mar Apr May Jun Jun Aug Sep Oct Nov Dec Jan Jun Jun

### **APPENDIX** FINANCIALS & ANALYSIS

Please note: reporting under IFRS since 2002 auditor Deloitte financials for the latest period are IFRS unaudited data by segments requires certain adjustments

#### 22 INCOME STATEMENT CONSOLIDATED

	1Q06	1Q05	06/05	2005	2004	2003	2002
NET SALES	99,2	65,4	52%	305,2	211,0	147,8	118,7
GROSS PROFIT	35,7	24,4	46%	117,8	80,2	59,8	46,0
EBITDA	5,4	3,5	57%	21,1	18,5	13,6	15,1
	5,5%	5,3%		6,9%	8,8%	<b>9</b> ,2%	12,7%
OPERATING INCOME	3,4	1,7	103%	13,3	11,5	8,4	10,4
NET INCOME	0,3	-1,1	n/a	8,3	0,7	1,0	3,3
	0,3%	-1,7%		2,7%	0,3%	0,7%	2,8%

#### 23 BALANCE SHEET CONSOLIDATED

	1Q06	2005	2004	2003	2002
N-CURRENT ASSETS	130,7	125,3	99,8	60,1	45,9
CURRENT ASSETS	131,2	119,4	72,5	53,0	38,8
TOTAL ASSETS	261,9	244,7	172,3	113,1	84,7
EQUITY	52,2	48,4	43,5	40,2	24,7
TOTAL DEBT	115,7	109,9	80,4	43,1	36,0
C-NT LIABILITIES*	70,5	64,2	40,0	24,9	20,1

\*Hereinafter Current Liabilities are non-interest bearing liabilities

#### 24 INCOME STATEMENT RETAIL

	1Q06	1Q05	06/05	2005	2004	2003	2002
NET SALES	72,7	45,6	60%	203,2	134,3	81,9	58,8
GROSS PROFIT	23,0	15,2	52%	67,2	45,4	26,3	19,2
GROSS MARGIN	33,6%	33,3%		33,1%	33,8%	32,1%	33%
EBITDA	1,0	1,4	-27%	2,6	6,4	1,8	2,6
	1,4%	3,1%		1,3%	4,8%	2,2%	4,4%
PERATING INCOME	-0,4	0,2	n/a	-3,0	2,6	-0,2	0,9


0

#### 25 BALANCE SHEET RETAIL

1Q06	2005	2004	2003	2002
95,4	85,4	59,5	21,9	15,7
59,6	52,4	29,1	15,6	13,1
155,1	137,8	88,6	37,4	28,8
5,0	4,6	4,7	1,9	11,1
54,6	47,2	27,3	35,3	15,2

N-CURRENT ASSETS CURRENT ASSETS TOTAL ASSETS LONG-TERM LIAB. C-NT LIABILITIES





#### 27 INCOME STATEMENT VEROPHARM

	1Q06	1Q05	06/05	2005	2004	2003	2002
NET SALES	19,7	15,0	32%	79,4	59,9	52,8	43,9
GROSS PROFIT	11,6	8,7	35%	47,0	32,7	31,3	23,4
<b>GROSS MARGIN</b>	59,1%	57,8%		<i>59,2%</i>	54,5%	59,2%	53,3%
EBITDA	5,5	3,2	72%	23,3	17,8	15,7	13,5
	27,7%	21,2%		29,3%	29,7%	<i>29,7%</i>	30,9%
PERATING INCOME	4,9	2,6	85%	21,2	14,8	12,7	10,5

#### 28 BALANCE SHEET VEROPHARM

	1Q06	2005	2004	2003	2002	
ſS	36,4	35,6	35, <b>9</b>	34,4	31,2	
S	58,2	54,5	38,7	32,4	23,4	
ר <b>צ</b> ו	94,6	90,1	74,6	66,8	54,5	
S	10,9	13,6	20,4	20,1	6,5	

N-CURRENT ASSETS --CURRENT ASSETS TOTAL ASSETS C-NT LIABILITIES

## **29 DISCLAIMER**

#### THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION, AND IS NOT AN OFFER TO SELL, OR AN INVITATION TO MAKE OFFERS TO PURCHASE, ANY SECURITIES IN THE RUSSIAN FEDERATION.

#### NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

## **30 HEALTHY, FIT & STRONG**

Address: 105082, Moscow, Bolshaya Pochtovaya 36

Tel.: +7 (495) 792-5207 Fax: +7 (495) 792-5206 E-mail: <u>ir@oao366.ru</u>

www.pharmacychain366.com